261 related articles for article (PubMed ID: 30998907)
21. N-(3,5-dimethylphenyl)-3-methoxybenzamide (A(3)B(5)) targets TRP-2 and inhibits melanogenesis and melanoma growth.
Lee EJ; Lee YS; Hwang S; Kim S; Hwang JS; Kim TY
J Invest Dermatol; 2011 Aug; 131(8):1701-9. PubMed ID: 21525883
[TBL] [Abstract][Full Text] [Related]
22. Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines.
Duarte D; Vale N
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769414
[TBL] [Abstract][Full Text] [Related]
23. Ethanolic Extract of
Castro DTH; Campos JF; Damião MJ; Torquato HFV; Paredes-Gamero EJ; Carollo CA; Rodrigues EG; de Picoli Souza K; Dos Santos EL
Oxid Med Cell Longev; 2019; 2019():5719483. PubMed ID: 31285786
[TBL] [Abstract][Full Text] [Related]
24. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells.
Liu ZJ; Zhou YJ; Ding RL; Xie F; Fu SZ; Wu JB; Yang LL; Wen QL
PLoS One; 2018; 13(7):e0200845. PubMed ID: 30052652
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Liu G; Marrinan CH; Taylor SA; Black S; Basso AD; Kirschmeier P; Robert Bishop W; Liu M; Long BJ
Anticancer Drugs; 2007 Sep; 18(8):923-31. PubMed ID: 17667598
[TBL] [Abstract][Full Text] [Related]
27. Anti-Melanoma Effects of Miconazole: Investigating the Mitochondria Involvement.
Scatozza F; Giardina MM; Valente C; Vigiano Benedetti V; Facchiano A
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612401
[TBL] [Abstract][Full Text] [Related]
28. Activation of cGMP-Dependent Protein Kinase Restricts Melanoma Growth and Invasion by Interfering with the EGF/EGFR Pathway.
Quadri M; Comitato A; Palazzo E; Tiso N; Rentsch A; Pellacani G; Marconi A; Marigo V
J Invest Dermatol; 2022 Jan; 142(1):201-211. PubMed ID: 34265328
[TBL] [Abstract][Full Text] [Related]
29. A three-drug nanoscale drug delivery system designed for preferential lymphatic uptake for the treatment of metastatic melanoma.
Doddapaneni BS; Kyryachenko S; Chagani SE; Alany RG; Rao DA; Indra AK; Alani AWG
J Control Release; 2015 Dec; 220(Pt A):503-514. PubMed ID: 26578440
[TBL] [Abstract][Full Text] [Related]
30. Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells.
Motawi TM; Sadik NA; Fahim SA; Shouman SA
Chem Biol Interact; 2015 May; 233():147-56. PubMed ID: 25863232
[TBL] [Abstract][Full Text] [Related]
31. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole.
Khalid MH; Tokunaga Y; Caputy AJ; Walters E
J Neurosurg; 2005 Jul; 103(1):79-86. PubMed ID: 16121977
[TBL] [Abstract][Full Text] [Related]
33. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
[TBL] [Abstract][Full Text] [Related]
34. Identification of ACA-28, a 1'-acetoxychavicol acetate analogue compound, as a novel modulator of ERK MAPK signaling, which preferentially kills human melanoma cells.
Satoh R; Hagihara K; Matsuura K; Manse Y; Kita A; Kunoh T; Masuko T; Moriyama M; Moriyama H; Tanabe G; Muraoka O; Sugiura R
Genes Cells; 2017 Jul; 22(7):608-618. PubMed ID: 28485554
[TBL] [Abstract][Full Text] [Related]
35. Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma.
Mohapatra S; Coppola D; Riker AI; Pledger WJ
Mol Cancer Res; 2007 Feb; 5(2):145-51. PubMed ID: 17314272
[TBL] [Abstract][Full Text] [Related]
36. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
37. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
[TBL] [Abstract][Full Text] [Related]
38. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
39. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
[TBL] [Abstract][Full Text] [Related]
40. Gene Duplication of the zebrafish kit ligand and partitioning of melanocyte development functions to kit ligand a.
Hultman KA; Bahary N; Zon LI; Johnson SL
PLoS Genet; 2007 Jan; 3(1):e17. PubMed ID: 17257055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
